



Ozempic, Mounjaro and Other GLP-1 Lawsuits: How Many Name Novo Nordisk or Eli Lilly

Original analysis of 4,030 records from the Federal Judicial Center, October 2023–June 2026 (filing dates). Published October 17, 2026. <https://settlementinsight.com/research/glp-1-lawsuits-novo-nordisk-vs-eli-lilly>

Of the 4,030 GLP-1 drug injury cases filed in federal court from October 2023 through June 2026, 3,346 (83.0%) named Novo Nordisk, maker of Ozempic and Wegovy, as first defendant, and 684 (17.0%) named Eli Lilly, maker of Mounjaro and Trulicity. That is about 4.9× as many cases against Novo Nordisk. Court records keep only the first-listed defendant, so cases that also name the other company are counted once.

83%

of GLP-1 injury cases name Novo Nordisk first

17%

of GLP-1 injury cases name Eli Lilly first


4,030

federal GLP-1 injury cases, Oct. 2023–June 2026



Federal GLP-1 injury cases by filing month

Top 12 of 32



Source: Settlement Insight analysis of data from the Federal Judicial Center
settlementinsight.com/research/glp-1-lawsuits-novo-nordisk-vs-eli-lilly · free to use with a link (CC BY 4.0)

What the Federal Court Records Show

- 1. Novo Nordisk is listed first in most cases.** Novo Nordisk entities are the first-named defendant in 3,346 of 4,030 GLP-1 product liability cases (83.0%); Eli Lilly is first in 684 (17.0%).
- 2. Eli Lilly's share rose, then fell back.** Cases naming Eli Lilly first made up 12.8% of filings in the second half of 2024, 25.5% in the second half of 2025 and 15.5% in the first half of 2026.

3. **The busiest month.** July 2025 was the busiest month in the series, with 534 new cases; Eli Lilly was named first in 32.0% of them.
4. **A third of cases lack an MDL code.** 1,263 of the cases (31.3%) carry no multidistrict litigation number in the federal court data; counting only cases coded to MDL 3094 would miss them.
5. **Our count matches the court panel's.** Excluding cases coded to the separate eye-injury MDL, we count 3,912 cases filed before July 1, 2026; the Judicial Panel on Multidistrict Litigation reported 3,882 total actions in MDL 3094 on that date, a difference of 0.8%.

How we measured

Data come from the Federal Judicial Center's Integrated Database of federal civil cases, as imported on October 10, 2026; the file contains cases filed through June 30, 2026. Calibration figures come from the Judicial Panel on Multidistrict Litigation's monthly MDL Statistics Reports, retrieved on October 17, 2026.

We included civil cases in the Eastern District of Pennsylvania (FJC district code 13) with nature-of-suit code 365 (personal injury product liability) or 367 (health care/pharmaceutical product liability), selected by the FJC filing date (filedate) from June 1, 2023 through June 30, 2026 (the first matching case was filed in October 2023). The MDL field had to read 3094, 3163 (eye injuries, centralized in December 2025), the obvious typo 0309 (2 Novo Nordisk direct filings into MDL 3094, which we count) or be empty. The first-listed defendant field had to contain LILLY, MOUNJARO or ZEPBOUND (assigned to Eli Lilly, checked first) or NOVO, NORDISK, OZEMPIC or WEGOVY (assigned to Novo Nordisk, which also catches spellings such as NOVA NORDISK, NOVO NORIDSK and the parent Novo Holdings); records matching none of these, such as a truncated "INC., ET AL", are excluded. Cases transferred in from other districts are counted in the Eastern District of Pennsylvania only; their original records elsewhere are not counted again.

Reopened cases appear as additional records with the same docket number within the district; per docket we kept the record with the earliest filing date (ties: lowest record id), which removed 37 rows. Each case is assigned to Novo Nordisk or Eli Lilly by the first-listed defendant; shares are cases for each company divided by all 4,030 cases.

To check completeness we compared the number of cases not coded to MDL 3163 filed before each JPML report date with the JPML's total historical actions for MDL 3094. On July 1, 2026, our count was 3,912 and the JPML figure 3,882.

Checked against published figures

- GLP-1 product liability actions in MDL 3094 (E.D. Pa.), total historical, as of July 1, 2026: published 3,882, our count 3,912 (0.77% apart). [JPML MDL Statistics Report: Pending MDL Dockets by Actions Pending, July 1, 2026](#)

Limitations

- Federal court records store only the first-listed defendant. A complaint against both Novo Nordisk and Eli Lilly counts for whichever company is listed first, so the data cannot show how many cases name both companies or which drug a plaintiff used.

- The company is not the same as the drug: Novo Nordisk makes Ozempic, Wegovy, Rybelsus and Saxenda; Eli Lilly makes Mounjaro and Trulicity. A case naming Eli Lilly first may concern Trulicity rather than Mounjaro.
- Cases without an MDL code that were filed since December 2025 may belong to MDL 3163 rather than MDL 3094; the federal data do not allow a clean split. The overall Novo Nordisk and Eli Lilly shares include both.
- Courts report new cases to the federal judiciary with a delay, and the database is updated in batches. Counts for the most recent months, especially the first half of 2026, may rise in later releases, so a comparison of the latest half-year with earlier ones is preliminary.
- The number of lawsuits reflects filing decisions by plaintiffs and their lawyers. It does not measure injury rates, the number of patients taking each drug or the merits of any claim. GLP-1 cases filed in state courts are not included.

Data files

- [GLP-1 lawsuits by first-named defendant](#) (CSV, 2 rows)
- [GLP-1 lawsuits by half-year and first-named defendant](#) (CSV, 6 rows)
- [GLP-1 lawsuits by filing month and first-named defendant](#) (CSV, 32 rows)
- [FJC case count vs. JPML MDL 3094 total actions](#) (CSV, 23 rows)

How to cite

Goldberg, L. (2026). GLP-1 Lawsuits in Federal Court — Cases by First-Named Defendant, Novo Nordisk vs. Eli Lilly (October 2023–June 2026) [Data set]. Settlement Insight. <https://settlementinsight.com/research/glp-1-lawsuits-novo-nordisk-vs-eli-lilly>

Free to reuse with attribution under CC BY 4.0. Please link to <https://settlementinsight.com/research/glp-1-lawsuits-novo-nordisk-vs-eli-lilly> as the source.